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Background: We investigated pretreatment fasting glucose as a predictor of patients’ important outcomes in breast
and colorectal cancers undergoing targeted therapies.
Patients and methods: In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents
from 1998 to 2009, we used the Kaplan–Meier method and the log-rank test to estimate survival through tertiles of
fasting glucose and the Cox proportional hazards model for multivariate analysis stratiﬁed by primary site of cancer and
including gender, age and body mass index.
Results: The median follow-up was 20 months (1–128). At 60 months, 65% of patients in the lowest tertile of fasting
glucose did not experiment disease progression compared with 34% in the highest tertile (P = 0.001). Seventy-six
percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P = 0.015). In
multivariate analysis, fasting glucose was a signiﬁcant predictor of time to disease progression only in breast cancer
patients in the ﬁrst tertile compared with the third (P = 0.017).
Conclusions: We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance
in breast cancer patients treated with targeted agents. Prospective studies are warranted to conﬁrm our ﬁndings.
Key words: breast cancer, colorectal cancer, fasting glucose, targeted agents
introduction
The increasing understanding of molecular pathways regulating
cell cycle, apoptosis, angiogenesis and invasion has provided
new targets in cancer therapy [1, 2]. The biologic agents
trastuzumab [a humanized blocking antibody against the
human epidermal growth factor receptor 2 (HER2)/neu
receptor], bevacizumab [an inhibitor against vascular
endothelial growth factor (VEGF)] and cetuximab [an mAb to
the epidermal growth factor receptor (EGFR)] received United
States Food and Drug Administration (US FDA) approval for
breast and colorectal cancer treatment [http://www.cancer.gov/
cancertopics/treatment/druginformation, (3 November 2011,
date last accessed)].
The identiﬁcation of biomarkers that are likely to predict
which patients will achieve the best response to these agents
represents a major challenge for contemporary oncologists.
The current tendency to characterize reliable predictors of
response to target therapy runs in parallel with the recently
emerging theme of the cross talk between different families of
receptors in response to ligand activation. In these respects,
extensive preclinical work supports the signaling interaction
between factors related to glucose metabolism (fasting glucose,
insulin-like growth factors), VEGFs and members of the erbB
tyrosine kinase family, such as the EGFR and HER2 [3–9].
Several epidemiologic studies support the role of glucose
metabolism in breast and colorectal carcinogenesis. Two
distinct meta-analyses of case–control and prospective cohort
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studies on diabetes and cancer have shown a 1.3-fold increased
risk for colorectal cancer and a 1.2-fold increased risk for
postmenopausal breast cancer in diabetic patients [10, 11]. In
major prospective cohort studies on glucose level and cancer
risk, increased glucose levels were consistently associated with
an increased risk of colorectal cancer [12]. Results for breast
cancer were somewhat more inconsistent. Elevated baseline
glucose levels appeared to be associated with an increased risk
of both pre- and postmenopausal breast cancer in Korean
women, but the association of interest was exclusively
conﬁrmed in postmenopausal women in the Austrian study
and in premenopausal women in the Swedish study [13–15].
Experimental data substantiate the hypothesis that increases
in blood glucose and factors related to its metabolism could
affect carcinogenesis through effects on cellular energy
metabolism. Abnormalities in glucose metabolism can turn
into enhanced sensitivity to oxidative stress and mitochondrial
dysfunction [16–19]. The resulting imbalance between the
production of highly reactive molecular species, chieﬂy oxygen
and nitrogen, and antioxidant defenses may signiﬁcantly affect
cancer risk, particularly in neoplasms with a strong metabolic
component such as breast and colorectal cancers [20].
The aim of the present study was to investigate whether, in
patients diagnosed with breast or colorectal cancers, circulating
levels of pretreatment fasting glucose were predictive of
resistance to targeted agents. Our working hypothesis was that
an association between lower levels of the investigated
biomarker and longer time to disease progression might exist
in these patients.
patients and methods
study participants and setting
This study was a multidisciplinary investigation coordinated by the Italian
National Cancer Institute Regina Elena in Rome together with La Sapienza
University in Rome. The Division of Medical Oncology B at Regina Elena
and the Department of Senology at G. Pascale provided data for breast
cancer patients. The Department of Medical Oncology and Endocrinology
at Federico II Medical School in Naples and the Department of Colorectal
Medical Oncology at G. Pascale contributed data for colorectal cancer
patients.
We included participants aged ≥18, diagnosed with histologically
conﬁrmed breast or colorectal cancer and who were treated with targeted
agents from 1998 to 2009. Breast cancer patients were considered suitable
for inclusion if they had received trastuzumab according to the indications
released by the US FDA [http://www.cancer.gov/cancertopics/druginfo/fda-
trastuzumab, (3 November 2011, date last accessed)]. We posed no
restrictions regarding trastuzumab use in early, locally advanced or
metastatic breast cancer, neither did we in reference to the administration
schedule. We included women who received trastuzumab as a single agent
or in combined regimens, at any dosage and duration. Women who
received trastuzumab repeatedly, either according to the same or different
schedules, were considered exclusively in reference to the ﬁrst use of this
drug.
We further included colorectal cancer patients who had received
bevacizumab and/or cetuximab according to the indications and
recommendations established by the US FDA [http://www.cancer.gov/
cancertopics/druginfo/fda-bevacizumab, http://www.cancer.gov/
cancertopics/druginfo/fda-cetuximab, (3 November 2011, date last
accessed)]. Again, we posed no restrictions regarding the administration
schedule. Patients who ﬁrst received bevacizumab and were subsequently
treated with cetuximab (or vice versa) were included in our database in
reference to the agent that was ﬁrst administered. If repeatedly treated with
either bevacizumab or cetuximab, patients were considered exclusively in
reference to the ﬁrst administration. We excluded patients with previous or
concomitant history of malignancy other than breast or colorectal cancer,
as well as patients diagnosed with either type I or type II diabetes based on
laboratory data and those whose pretreatment fasting glucose was ≥126
mg/dl [21].
data retrieving
Medical record retrieving was based on the close collaboration between a
speciﬁcally trained medical assistant and the medical oncologists in charge
of patient management and follow-up at the participating institutions. We
reviewed the cases of breast and colorectal cancer patients diagnosed and
treated between January 1998 and March 2009. For each patient, we sought
to include data on demographics and anthropometrics, particularly body
weight and height at baseline and at the end of follow-up. We further
retrieved data on cancer features at the time of diagnosis (e.g. stage of
disease), ascertainment of HER2/neu receptor status in breast cancer and
EGFR and KRAS status in metastatic colorectal cancer patients,
administered therapy and follow-up.
laboratory assays
Pretreatment fasting glucose was measured on venous blood collected at
the time of (histologically conﬁrmed) breast or colorectal cancer diagnosis
and previous to any form of cancer therapy. Blood samples were collected
in standardized conditions claiming overnight fasting and time at blood
drawing between 7 and 10 am.
Glucose concentrations were locally determined using a Cobas analyzer
with Roche hexokinase reagent. Central laboratories at the participating
institutions were certiﬁed to an international management systems
standard called ISO 9001 (ISO 9001:2000/2008).
immunohistochemistry, silver in situ hybridization
and FISH
HER2 positivity was determined locally and deﬁned as
immunohistochemical staining of 3+ or 2+ with evidence of gene
ampliﬁcation at FISH. HER2 immunostaining was carried out using the
polyclonal antibody A0485 (Dako, Milan, Italy). HER2
immunohistochemistry (IHC) positivity was determined according to the
American Society of Clinical Oncology-College of American Pathologists
(ASCO--CAP) guidelines [22].
Silver in situ hybridization (SISH) was used to assess HER2 gene and
Chr17 status (Inform HER2 DNA Probe, Inform Chr17 probe; Ventana,
Roche Diagnostic, Milan, Italy). The HER2 and centromere on
chromosome 17 dinitrophenol-labeled probes were visualized using the
rabbit anti-dinitrophenol primary antibody and the ultraVIEW SISH
Detection Kit. Case deﬁnition was carried out according to the ASCO–CAP
guidelines [22].
IHC, DNA extraction and KRAS mutation analysis
Immunohistochemical stains for EGFR were locally carried out on 5-μ
parafﬁn-embedded tissue sections using DAKO EGFR PharmDX kit
(Dako). EGFR expression was deﬁned positive as any membrane staining
above background level was visualized. Results were further interpreted
according to a quantitative score.
DNA for KRAS mutation analysis was extracted using the DNA
extraction kit QIAmp DNA kit (Qiagen-Explera, Jesi, Italy). The DNA was
used in a PCR to amplify the region of exon 2 of KRAS-containing codons
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12 and 13. The PCR products were puriﬁed using Nucleospin Extract II
Puriﬁcation kit (M-Medical, Milan, Italy), sequenced using BigDye
Terminator v 3.1 kit (Applied Biosystems, Monza, Italy) and analyzed with
an ABI 3130 capillary electrophoresis system (Applied Biosystems). The
presence of a heterozygous KRAS mutation was deﬁned as the appearance
of a mutant peak with a height of at least one-third of that of the wild type.
In all the colorectal cancer patients, DNA was extracted from the primary
tumor.
Extensive details on the procedures described above will be provided
upon request.
statistical analyses
We examined distributions and computed descriptive statistics for all the
variables of interest. We described the study participants’ features (overall
and by cancer site) and reported them through tertiles of pretreatment
fasting glucose. We used means and standard deviations for continuous
data as well as frequencies and percentage values for categorical data.
Existing differences between mean values were evaluated using the
Student’s T or one-way analysis of variance test dependently on the
number (two or more) of groups compared. We used the Pearson’s Chi-
square test of independence (two tailed) to assess the relationships between
categorical variables.
We carried out survival analyses using the Kaplan–Meier product-limit
method and applied the log-rank test to compare the survival curves
through tertiles of fasting glycemia. Time to the development of resistance
to targeted agents was calculated as the interval between the date at ﬁrst
trastuzumab/bevacizumab/cetuximab administration and (the date at)
disease progression, last follow-up or death by cancer, whichever came ﬁrst.
We conducted survival analyses on the overall sample and on subsets
obtained stratifying by cancer site, gender and, in women, menopausal
status. Given the recognized role of KRAS status in predicting patients’
important outcomes in metastatic colorectal cancer treated with cetuximab
[23], we conducted a set of separate analyses excluding the 46 patients with
unknown KRAS status.
The Cox proportional hazards model was used to further test the
predictive role of fasting glucose on patients’ important outcomes in
multivariate analyses. Gender, age and body mass index (BMI) at cancer
diagnosis were included as covariates. The model was further stratiﬁed by
primary site of cancer (i.e. breast versus colorectal cancer). We also used
stage at cancer diagnosis as a proxy variable for cancer burden and tested it
for interaction in a separate Cox model.
Data on age at cancer diagnosis were not available for 10 patients, while
BMI was unknown for 38 patients. Missing values for these two variables
were replaced by their means calculated by cancer site and tertiles of fasting
glucose, respectively.
We considered P values <0.05 statistically signiﬁcant. All statistical
analyses were carried out with the SPSS statistical software version 18
(SPSS Inc., Chicago, IL).
results
Overall, four hundred and twenty cancer patients were
included in our analyses. Two hundred and eighteen patients
had received a breast cancer diagnosis, while two hundred and
two patients had been diagnosed with colorectal cancer. Mean
age at cancer diagnosis was 53.4 ± 12.8. Females were more
represented than men (298 versus 122), as well as
postmenopausal women among females (160 of 298).
Participants were more commonly married (221 of 420) than
separated, single or widowed. Data related to smoking status
were only partly available, with current/past smokers
representing 13.6% of our sample. Means and standard
deviations for height (cm), weight (kg) and BMI (m2/kg) at
baseline were 162.6 ± 7.9, 66.2 ± 13.1 and 25.5 ± 4.3,
respectively. The median duration of follow-up was 20 months
(1–128; data available upon request).
In Table 1, our study participants were compared by
primitive cancer site. Cancer patients signiﬁcantly differed by
age at cancer diagnosis, menopausal status, marital status,
anthropometrics at baseline and stage at cancer diagnosis.
Breast cancer patients were more likely to be younger,
premenopausal and with a lower disease stage at cancer
diagnosis when compared with colorectal cancer patients (49.4
± 12.2 versus 57.8 ± 12.1, P < 0.001; 74.5% versus 25.5%, P =
0.025 and 98.8% versus 1.2%, P < 0.001, respectively).
Separated, single and widowed participants were signiﬁcantly
more common among breast cancer patients than in the
colorectal cancer group (92.9%, 76.5% and 66.7% versus 7.1%,
23.5% and 33.3%, P = 0.019, respectively). Furthermore,
women diagnosed with breast cancer showed lower height and
body weight at baseline (161.2 ± 6.5 versus 165 ± 9.2, P = 0.008,
respectively).
Cancer patient characteristics through tertiles of
pretreatment fasting glucose appear in Table 2. Patients in the
ﬁrst tertile were more likely to be younger, single, female and,
if so, premenopausal when compared with participants in the
third tertile (48.9 ± 13.6 versus 57.5 ± 11.4, P < 0.001; 60%
Table 1. Study participant characteristics by primitive cancer site
Primitive cancer site P valuea
Colorectal Breast
Age at cancer diagnosis (years),
mean ± SD
57.8 ± 12.1 49.4 ± 12.2 <0.001
Gender, n (%)
Male 122 (100.0) 0 (0) <0.001
Female 96 (32.2) 202 (67.8)
Menopausal status, n (%)
Premenopausal 35 (25.5) 102 (74.5) 0.025
Postmenopausal 61 (38.1) 99 (61.9)
Marital status, n (%)
Married 88 (39.8) 133 (60.2) 0.019
Separated 1 (7.1) 13 (92.9)
Single 12 (23.5) 39 (76.5)
Widowed 7 (33.3) 14 (66.7)
Smoking status, n (%)
Yes 14 (24.6) 43 (75.4) 0.451
No 34 (19.2) 143 (80.8)
Height at baseline (cm), mean ± SD 165 ± 9.2 161.2 ± 6.5 0.001
Weight at baseline (kg), mean ± SD 69.1 ± 12.8 64.8 ± 13.1 0.008
BMI at baseline (m2/kg), mean ± SD 25.7 ± 3.8 25.2 ± 4.8 0.341
Stage at cancer diagnosis, n (%) (TNM)
I 1 (1.2) 85 (98.8) <0.001
II 4 (100.0) 0 (0)
III 11 (91.7) 1 (8.3)
IV 87 (51.5) 82 (48.5)
aComparisons were carried out with the Pearson’s Chi-square test for the
categorical variables and Student’s T test for continuous variables.
SD, standard deviation; BMI, body mass index; TNM, tumor–node–
metastasis.
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versus 16%, P < 0.001; 39.3% versus 27.8%, P = 0.001 and
51.9% versus 18.5%, P < 0.001; respectively). Cancer patients in
the ﬁrst tertile of pretreatment fasting glucose were also more
commonly smokers and showed lower body weight and BMI at
baseline (49.1% versus 22.8%, P < 0.001; 63.3 ± 12.9 versus
70.2 ± 12.4, P = 0.001 and 24.8 ± 4.4 versus 26.3 ± 4.1, P =
0.029, respectively). Figure 1 shows the time to disease
progression through tertiles of pretreatment fasting glucose for
the overall sample. At 60 months, 65% of cancer patients in
the lowest tertile (≤88 mg/dl) did not experience disease
progression compared with 34% in the second and third
tertiles (P = 0.001). When stratifying by gender (Figure 2), 76%
of female participants in the lowest tertile showed no
progression compared with 49% in the remaining tertiles (P =
0.015). We further stratiﬁed analyses by menopausal status and
primitive cancer site. In supplemental Figure S1 (available at
Annals of Oncology online), premenopausal women in the
lowest tertile showed a longer, although of only borderline
signiﬁcance, time to disease progression compared with
women in the highest tertile (74% versus 39%, P = 0.053). In
supplemental Figure S2 (available at Annals of Oncology
online), there was an indication for longer time to disease
progression in breast cancer participants with lower
pretreatment glucose levels compared with breast cancer
patients in the highest tertile (87% versus 54%, P = 0.053). The
exclusion of the 46 colorectal cancer patients with unknown
KRAS status did not affect our estimates (data available upon
request).
Cox proportional hazards models of variables associated
with time to disease progression in breast and colorectal cancer
patients overall and by site of primitive cancer are presented in
supplemental Tables S1 and S2 (available at Annals of
Oncology online). As shown in Table S1 (available at Annals of
Oncology online), in multivariate analysis including gender, age
at cancer diagnosis and BMI as covariates, the predictive role
of pretreatment fasting glucose on time to disease progression
was conﬁrmed. Cancer patients in the second and third tertiles
showed a signiﬁcantly shorter time to disease progression
compared with those in the ﬁrst tertile [hazard ratio (HR) 1.86,
95% conﬁdence interval (CI) 1.10–3.16 and HR 1.76, 95% CI
1.01–3.08, respectively]. However, when stratiﬁed by primary
site of cancer (Table S2, available at Annals of Oncology
online), the Cox model conﬁrmed these results only in breast
cancer patients in the ﬁrst tertile compared with the third (HR
4.07, 95% CI 1.29–12.85). The Cox model testing the
interaction between stage at cancer diagnosis and pretreatment
fasting glucose produced no signiﬁcant results (P = 0.640).
discussion
According to the results of our historic cohort study, in breast
and metastatic colorectal cancer patients treated with targeted
agents, lower levels of pretreatment fasting glucose were
predictive of longer time to disease progression. When
stratifying by gender, pretreatment fasting glucose was a
stronger predictor in women than in men. There was also a
Table 2. Study participant characteristics by tertiles of pretreatment fasting glucose
Tertiles of glycemia at baseline (mg/dl) P valuea
≤88 89–98 ≥99
Age at cancer diagnosis (years), mean ± SD 48.9 ± 13.6 54.4 ± 11.6 57.5 ± 11.4 <0.001
Gender, n (%)
Male 24 (20.3) 44 (37.3) 50 (42.4) 0.001
Female 116 (39.3) 97 (32.9) 82 (27.8)
Menopausal status, n (%)
Premenopausal 70 (51.9) 40 (29.6) 25 (18.5) <0.001
Postmenopausal 46 (28.9) 57 (35.9) 56 (35.2)
Marital status, n (%)
Married 78 (35.6) 76 (34.7) 65 (29.7) <0.001
Separated 5 (35.7) 3 (21.4) 6 (42.9)
Single 30 (60.0) 12 (24.0) 8 (16.0)
Widowed 4 (19.0) 3 (14.3) 14 (66.7)
Smoking status, n (%)
Yes 28 (49.1) 16 (28.1) 13 (22.8) <0.001
No 72 (40.7) 59 (33.3) 46 (26.0)
Height at baseline (cm), mean ± SD 162.5 ± 8.1 162.4 ± 7.6 162.8 ± 8.0 0.952
Weight at baseline (kg), mean ± SD 63.3 ± 12.9 66.2 ± 13.2 70.2 ± 12.4 0.001
BMI at baseline (m2/kg), mean ± SD 24.8 ± 4.4 25.4 ± 4.3 26.3 ± 4.1 0.029
Stage at cancer diagnosis, n (%) (TNM)
I 36 (41.9) 29 (33.7) 21 (24.4) 0.508
II 1 (25) 1 (25) 2 (50)
III 3 (27.3) 2 (18.2) 6 (54.5)
IV 66 (40.0) 51 (30.9) 48 (29.1)
aComparisons were carried out with the Pearson’s Chi-square test for categorical variables and one-way ANOVA for continuous variables.
SD, standard deviation; BMI, body mass index; TNM, tumor–node–metastasis; ANOVA, analysis of variance.
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suggestion for a role of menopausal status and primitive cancer
site in modifying the association of interest, with results of
borderline signiﬁcance in premenopausal women and in
patients diagnosed with breast cancer. Our results do not
support the existence of a dose–response relationship between
the biomarker of interest and treatment outcome. Indeed,
breast and colorectal cancer patients in the second and third
tertiles showed no difference in terms of time to disease
progression. Though on highly speculative ground, this seems
to suggest that increases in pretreatment fasting glucose might
affect treatment outcomes across a relatively restricted range of
normal values. In our historical cohort, the latter range seems
to fall within the ﬁrst tertile (i.e. ≤88 mg/dl). Conversely,
further increases do not necessarily translate into substantial
worsening of the outcomes considered. Our ﬁgures seemed to
suggest a relevant role of primary site of cancer on the
association of interest, which was conﬁrmed in multivariate
analyses stratiﬁed accordingly. The Cox model showed a
signiﬁcant longer time to disease progression exclusively in
breast cancer patients in the ﬁrst tertile compared with the
third (P = 0.017). Conversely, fasting glucose had no predictive
role on time to disease progression in colorectal cancer
patients. Differences in tumor burden between these two
subpopulations might help explain this result. Though we lack
adequate data to precisely estimate the tumor burden, based
upon the stage at cancer diagnosis and indications to
trastuzumab administration, we might speculate that our breast
cancer patients were quite equally distributed among the early
and advanced stages. Conversely, most of the colorectal cancer
patients were metastatic at diagnosis and all of them were
metastatic at target therapy administration. In these patients,
the investigated association might have been obscured by the
greater cancer burden and the consequent more rapid onset of
drug resistance. However, when testing the interaction between
stage at diagnosis and pretreatment fasting glucose, no
signiﬁcant results were obtained.
The retrospective nature of our study design represents the
main source of our study limitations. The retrospective design
has limited us in availability of data potentially relevant to the
investigated association, e.g. smoking status, number and site
of metastatic involvement. This is extremely common when
relying on data primarily collected for clinical purposes in a
clinical setting. Furthermore, among the potential predictors of
resistance to targeted agents related to glucose metabolism, we
exclusively investigated fasting glucose while not considering
other potentially relevant markers, such as baseline insulin,
insulin-like growth factor-I (IGF-I) and insulin-like growth
factor proteins. Unfortunately, no biological samples and
related consent forms were available for the included
participants. Finally, we based our analyses on a single
pretreatment fasting glucose determination. We are conscious
that glucose levels from a single serum sample may not
adequately characterize the exposure of interest. On the other
hand, although available, the results of further glucose
determinations may have been inﬂuenced by administered
treatments.
Our study also has several important strengths. First, for
each of our patients, the standard assay of pretreatment fasting
glucose was run by the central laboratory of the pertinent
participating cancer institute. This is a major strength of our
study. Indeed, institutional central laboratories have active and
ongoing quality control protocols, which ensure high-quality
biomarker data. Secondly, given that data were collected via
retrieval of medical records, this study provided a relatively
Figure 1. Time to disease progression in months.
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inexpensive and fast way to investigate the stated hypothesis.
Abstraction from the medical records was carried out by a
speciﬁcally trained medical assistant in close collaboration with
the medical oncologists who had prospectively followed the
patients included in our analyses. This increases our
conﬁdence in the quality of the information gathered.
Furthermore, the pretreatment assessment of the exposure of
interest (fasting glucose) should preserve the temporality of the
observed associations, an important criterion to assess
causality. Finally, we explored a completely novel and
potentially highly informative relationship.
Our study results are barely comparable with the currently
available epidemiologic evidence. It is worthy to note that all
previous research in the pertinent area, that is the impact of
glucose-related metabolism on breast and colorectal
carcinogenesis, has focused either on breast and/or colorectal
Figure 2. Time to disease progression in months. Analyses stratiﬁed by gender.
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cancer incidence and/or mortality. Among the prospective
studies conducted so far, only a few found no associations [24,
25], while the majority showed signiﬁcantly increased risk of
cancer development or death with increased glucose [10–15,
24, 26–37].
From a biological perspective, the interplay between factors
related to glucose metabolism and the molecular targets of the
therapeutic agents of interest might help interpret our study
results. Indeed, data from the preclinical setting have shown that
insulin promotes the transcription of several genes, including
those encoding the glucose transporter GLUT1 and VEGF [3].
IGF-I increases the expression of VEGF messenger RNA and the
production of VEGF protein by COLO 205 colon carcinoma cells
[4] and enhances the expression of VEGF in osteoblasts [5]. In
addition, evidence of the tight interplay between insulin-like
growth factor-I receptor (IGF-IR) and EGFR emerges from a
number of studies. IGF-1R activation is crucial for the mitogenic
and transforming activity of the EGFR [6, 7].
In conclusion, the present study provides novel evidence on
the predictive role of pretreatment fasting glucose levels in the
development of resistance to cancer treatment. These ﬁndings
may have important clinical implications in the management
and prognosis for cancer patients. In fact, if additional
prospective and experimental studies corroborate our ﬁndings,
two main consequences could be hypothesized. First, these
patients would be subject to very tight blood sugar control.
Secondly, the threshold for treatment of blood glucose would
change dramatically. This could potentially affect time to
disease progression and increase survival, leading the way to
new avenues for exploring underlying resistance to targeted
agent-based regimens.
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Evaluation of glomerular ﬁltration rate estimation by
Cockcroft–Gault, Jelliffe, Wright and Modiﬁcation of
Diet in Renal Disease (MDRD) formulae in oncology
patients
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Background: The aim was to evaluate the accuracy of Cockcroft–Gault, Jelliffe, Wright and Modiﬁcation of Diet in
Renal Disease (MDRD) formulae as a substitute for the gold standard measure of glomerular ﬁltration rate (GFR) using
chromium 51 EDTA.
Patients and methods: Retrospective analysis of GFR measurements in oncology patients from a University
Teaching Hospital over 3 years was carried out. Bias and precision of estimates of GFR were compared with measured
GFR.
Results: Six hundred and sixty patients with measured GFR (median 90 ml/min, range 23–179 ml/min) were identiﬁed.
Cockcroft–Gault produced the smallest bias (median percentage error −1.4%) and highest precision (median absolute
percentage error 14.0%) and was the most accurate for carboplatin dosing. For patients >30% over their ideal body
weight (IBW), using IBW + 30% in the Cockcroft–Gault formula was more precise than using actual body weight or
IBW. The Wright formula was most accurate for patients aged 70 + years and patients with a body mass index (BMI)
≥30 but overestimated GFR when GFR < 50 ml/min.
Conclusions: When measured GFR is unavailable, we advise estimating GFR using the Cockcroft–Gault formula and
using IBW + 30% for patients weighing >30% over their IBW. If the GFR is ≥50 ml/min and the patient is >70 years
and/or BMI ≥30, the Wright formula gives the best estimate of GFR.
Key words: carboplatin, Cockcroft–Gault, estimation, formula, glomerular ﬁltration rate
introduction
Many patients having therapy for cancer require assessment of
renal function for dosing of cytotoxic chemotherapy agents.
Carboplatin in particular is calculated using a targeted area
under the plasma carboplatin concentration time curve (AUC)
instead of using body surface area (BSA) [1]. The Calvert
equation is used for dosing carboplatin and incorporates the
glomerular ﬁltration rate (GFR) as its key variable (Figure 1). It
is therefore essential to establish an accurate GFR. Early trials
used 24-h urine creatinine collection and inulin excretion;
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